Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (1 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (5)
Type
Type
Guidance (302)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (10)
Medical technologies guidance (11)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (302)
Apply filters
Showing 271 to 280 of 302
Sort by
Title
Date
Apply sorting
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Tislelizumab for previously treated advanced oesophageal squamous cell cancer [ID4070]
Technology appraisal guidance
TBC
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]
Technology appraisal guidance
TBC
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]
Technology appraisal guidance
TBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]
Technology appraisal guidance
TBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]
Technology appraisal guidance
TBC
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Technology appraisal guidance
TBC
Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy [ID3935]
Technology appraisal guidance
TBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]
Technology appraisal guidance
10 September 2025
Treatments for non-small-cell lung cancer [ID6234]
Technology appraisal guidance
TBC
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]
Technology appraisal guidance
24 July 2024
Previous page
1
…
26
27
Current page
28
29
30
31
Page
28
of
31
Next page
Results per page
10
25
50
All
Back to top